HDL and endothelial protection: Examining evidence from HDL inherited disorders

Clinical Lipidology

Volumn 8, Issue 3, 2013, Pages 361-370

  Gomaraschi, Monica ^a   Ossoli, Alice ^a   Vitali, Cecilia ^a   Calabresi, Laura ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

apoA I; atherosclerosis; CETP deficiency; endothelium; genetic HDL disorders; HDL; LCAT deficiency

Indexed keywords

ABC TRANSPORTER A1; APOLIPOPROTEIN A1; CELL ADHESION MOLECULE; CHOLESTEROL ESTER TRANSFER PROTEIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC OXIDE; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PROSTACYCLIN;

ABCA1 GENE; AMINO TERMINAL SEQUENCE; APOA1 GENE; CELL FUNCTION; CELL PROLIFERATION; CELL PROTECTION; CETP GENE; CHOLESTEROL TRANSPORT; ENDOTHELIUM; ENZYME PHOSPHORYLATION; FAMILIAL HYPOALPHALIPOPROTEINEMIA; GENE; HOMEOSTASIS; HUMAN; LCAT GENE; LECITHIN CHOLESTEROL ACYLTRANSFERASE DEFICIENCY; LIPOPROTEIN BLOOD LEVEL; MUTATIONAL ANALYSIS; NONHUMAN; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TANGIER DISEASE;

EID: 84878711390     PISSN: 17584299     EISSN: 17584302     Source Type: Journal    
DOI: 10.2217/clp.13.30     Document Type: Review

References (90)

1. Calabresi L, Gomaraschi M, Franceschini G. High-density lipoprotein quantity or quality for cardiovascular prevention? Curr. Pharm. Des. 16, 1494-1503 (2010).
2. Rye KA, Barter PJ. Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I. Arterioscler. Thromb. Vasc. Biol. 24, 421-428 (2004).
3. Heinecke JW. The protein cargo of HDL: implications for vascular wall biology and therapeutics. J. Clin. Lipidol. 4, 371-375 (2010).
4. Franceschini G, Maderna P, Sirtori CR. Reverse cholesterol transport: physiology and pharmacology. Atherosclerosis 88, 99-107 (1991).
5. Rothblat GH, Phillips MC. High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr. Opin. Lipidol. 21, 229-238 (2010).
6. Favari E, Calabresi L, Adorni MP et al. Small discoidal pre-beta1 HDL particles are efficient acceptors of cell cholesterol via ABCA1 and ABCG1. Biochemistry 48, 11067-11074 (2009).
7. Ji Y, Wang N, Ramakrishnan R et al. Hepatic scavenger receptor BI promotes rapid clearance of high density lipoprotein free cholesterol and its transport into bile. J. Biol. Chem. 274, 33398-33402 (1999).
8. Tabet F, Rye KA. High-density lipoproteins, inflammation and oxidative stress. Clin. Sci. 116, 87-98 (2009).
9. Mineo C, Shaul PW. Novel biological functions of high-density lipoprotein cholesterol. Circ. Res. 111, 1079-1090 (2012).
10. Calabresi L, Gomaraschi M, Franceschini G. Endothelial protection by high-density lipoproteins: from bench to bedside. Arterioscler. Thromb. Vasc. Biol. 23, 1724-1731 (2003).
11. Kuvin JT, Ramet ME, Patel AR et al. A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. Am. Heart J. 144, 165-172 (2002).
12. Ramet ME, Ramet M, Lu Q et al. High-density lipoprotein increases the abundance of eNOS protein in human vascular endothelial cells by increasing its half-life. J. Am. Coll. Cardiol. 41, 2288-2297 (2003).
13. Gomaraschi M, Baldassarre D, Amato M et al. Normal vascular function despite low levels of high-density lipoprotein cholesterol in carriers of the apolipoprotein A-I(Milano) mutant. Circulation 116, 2165-2172 (2007).
14. Yuhanna IS, Zhu Y, Cox BE et al. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat. Med. 7, 853-857 (2001).
15. Fulton D, Gratton JP, Sessa WC. Post-translational control of endothelial nitric oxide synthase: why isn't calcium/calmodulin enough? J. Pharmacol. Exp. Ther. 299, 818-824 (2001).
16. Mineo C, Yuhanna IS, Quon MJ, Shaul PW. High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases. J. Biol. Chem. 278, 9142-9149 (2003).
17. Norata GD, Callegari E, Marchesi M et al. High-density lipoproteins induce transforming growth factor-beta2 expression in endothelial cells. Circulation 111, 2805-2811 (2005).
18. Nofer JR, van der Giet M, Tolle M et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J. Clin. Invest. 113, 569-581 (2004).
19. Christoffersen C, Obinata H, Kumaraswamy SB et al. Endothelium-protective sphingosine-1-phosphate provided by HDL associated apolipoprotein M. Proc. Natl. Acad. Sci. USA 108, 9613-9618 (2011).
20. Pomerantz KB, Fleisher LN, Tall AR, Cannon PJ. Enrichment of endothelial cell arachidonate by lipid transfer from high density lipoproteins: relationship to prostaglandin I2 synthesis. J. Lipid Res. 26, 1269-1276 (1985).
21. Tamagaki T, Sawada S, Imamura H et al. Effects of high-density lipoproteins on intracellular pH and proliferation of human vascular endothelial cells. Atherosclerosis 123, 73-82 (1996).
22. Van Sickle WA, Wilcox HG, Malik KU, Nasjletti A. High density lipoprotein-induced cardiac prostacyclin synthesis in vitro: relationship to cardiac arachidonate mobilization. J. Lipid Res. 27, 517-522 (1986).
23. Kaul S, Coin B, Hedayiti A et al. Rapid reversal of endothelial dysfunction in hypercholesterolemic apolipoprotein E-null mice by recombinant apolipoprotein A-I(Milano)-phospholipid complex. J. Am. Coll. Cardiol. 44, 1311-1319 (2004).
24. Kuvin JT, Patel AR, Sidhu M et al. Relation between high-density lipoprotein cholesterol and peripheral vasomotor function. Am. J. Cardiol. 92, 275-279 (2003).
25. Lupattelli G, Marchesi S, Roscini A et al. Direct association between high-density lipoprotein cholesterol and endothelial function in hyperlipemia. Am. J. Cardiol. 90, 648-650 (2002).
26. O'Brien SF, Watts GF, Playford DA et al. Low-density lipoprotein size, high-density lipoprotein concentration, and endothelial dysfunction in non-insulin-dependent diabetes. Diabet. Med. 14, 974-978 (1997).
27. Zhang X, Zhao SP, Li XP, Gao M, Zhou QC. Endothelium-dependent and -independent functions are impaired in patients with coronary heart disease. Atherosclerosis 149, 19-24 (2000).
28. Spieker LE, Sudano I, Hurlimann D et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 105, 1399-1402 (2002).
29. Bisoendial RJ, Hovingh GK, Levels JH et al. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation 107, 2944-2948 (2003).
30. Davies MJ, Gordon JL, Gearing AJ et al. The expression of the adhesion molecules ICAM 1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. J. Pathol. 171, 223-229 (1993).
31. Gearing AJ, Newman W. Circulating adhesion molecules in disease. Immunol. Today 14, 506-512 (1993).
32. Barter PJ, Baker PW, Rye KA. Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells. Curr. Opin. Lipidol. 13, 285-288 (2002).
33. Calabresi L, Franceschini G, Sirtori CR et al. Inhibition of VCAM-1 expression in endothelial cells by reconstituted high density lipoproteins. Biochem. Biophys. Res. Commun. 238, 61-65 (1997).
34. Xia P, Vadas MA, Rye KA, Barter PJ, Gamble Jr. High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway. A possible mechanism for protection against atherosclerosis by HDL. J. Biol. Chem. 274, 33143-33147 (1999).
35. Kimura T, Tomura H, Mogi C et al. Role of scavenger receptor class B type I and sphingosine 1-phosphate receptors in high-density lipoprotein-induced inhibition of adhesion molecule expression in endothelial cells. J. Biol. Chem. 281, 37457-37467 (2006).
36. McGrath KC, Li XH, Puranik R et al. Role of 3beta-hydroxysteroid-Delta 24 reductase in mediating antiinflammatory effects of high-density lipoproteins in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 29, 877-882 (2009).
37. Ashby DT, Rye KA, Clay MA et al. Factors influencing the ability of HDL to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 18, 1450-1455 (1998).
38. Gomaraschi M, Calabresi L, Rossoni G et al. Anti-inflammatory and cardioprotective activities of synthetic high-density lipoprotein containing apolipoprotein A-I mimetic peptides. J. Pharmacol. Exp. Ther. 324, 776-783 (2008).
39. Baker PW, Rye KA, Gamble JR, Vadas MA, Barter PJ. Phospholipid composition of reconstituted high density lipoproteins influences their ability to inhibit endothelial cell adhesion molecule expression. J. Lipid Res. 41, 1261-1267 (2000).
40. Calabresi L, Gomaraschi M, Villa B et al. Elevated soluble cellular adhesion molecules in subjects with low HDL cholesterol. Arterioscler. Thromb. Vasc. Biol. 22, 656-661 (2002).
41. Birjmohun RS, van Leuven SI, Levels JH et al. High-density lipoprotein attenuates inflammation and coagulation response on endotoxin challenge in humans. Arterioscler. Thromb. Vasc. Biol. 27, 1153-1158 (2007).
42. Nicholls SJ, Lundman P, Harmer JA et al. Consumption of saturated fat impairs the anti-inflammatory properties of high-density lipoproteins and endothelial function. J. Am. Coll. Cardiol. 48, 715-720 (2006).
43. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation 115, 1285-1295 (2007).
44. Nofer JR, Levkau B, Wolinska I et al. Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL associated lysosphingolipids. J. Biol. Chem. 276, 34480-34485 (2001).
45. Sugano M, Tsuchida K, Makino N. High-density lipoproteins protect endothelial cells from tumor necrosis factor-alpha-induced apoptosis. Biochem. Biophys. Res. Commun. 272, 872-876 (2000).
46. Tso C, Martinic G, Fan WH et al. High-density lipoproteins enhance progenitor-mediated endothelium repair in mice. Arterioscler. Thromb. Vasc. Biol. 26, 1144-1149 (2006).
47. Noor R, Shuaib U, Wang CX et al. High-density lipoprotein cholesterol regulates endothelial progenitor cells by increasing eNOS and preventing apoptosis. Atherosclerosis 192, 92-99 (2007).
48. Huang CY, Lin FY, Shih CM et al. Moderate to high concentrations of high-density lipoprotein from healthy subjects paradoxically impair human endothelial progenitor cells and related angiogenesis by activating rho-associated kinase pathways. Arterioscler. Thromb. Vasc. Biol. 32, 2405-2417 (2012).
49. Edmondson AC, Brown RJ, Kathiresan S et al. Loss-of-function variants in endothelial lipase are a cause of elevated HDL cholesterol in humans. J. Clin. Invest. 119, 1042-1050 (2009).
50. Gehrisch S, Kostka H, Tiebel M et al. Mutations of the human hepatic lipase gene in patients with combined hypertriglyceridemia/ hyperalphalipoproteinemia and in patients with familial combined hyperlipidemia. J. Mol. Med. 77, 728-734 (1999).
51. Vergeer M, Korporaal SJ, Franssen R et al. Genetic variant of the scavenger receptor BI in humans. N. Engl. J. Med. 364, 136-145 (2011).
52. Sorci-Thomas MG, Thomas MJ. The effects of altered apolipoprotein A-I structure on plasma HDL concentration. Trends Cardiovasc. Med. 12, 121-128 (2002).
53. Obici L, Franceschini G, Calabresi L et al. Structure, function and amyloidogenic propensity of apolipoprotein A-I. Amyloid 13, 191-205 (2006).
54. Franceschini G, Sirtori CR, Capurso A, Weisgraber KH, Mahley RW. A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J. Clin. Invest. 66, 892-900 (1980).
55. Sirtori CR, Calabresi L, Franceschini G et al. Cardiovascular status of carriers of the apolipoprotein A-IMilano mutant. The Limone sul Garda Study. Circulation 103, 1949-1954 (2001).
56. Hovingh GK, Brownlie A, Bisoendial RJ et al. A novel apoA I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease. J. Am. Coll. Cardiol. 44, 1429-1435 (2004).
57. Roma P, Gregg RE, Meng MS et al. In vivo metabolism of a mutant form of apolipoprotein A-I, apo A-IMilano, associated with familial hypoalphalipoproteinemia. J. Clin. Invest. 91, 1445-1452 (1993).
58. Franceschini G, Calabresi L, Chiesa G et al. Increased cholesterol efflux potential of sera from apoA IMilano carriers and transgenic mice. Arterioscler. Thromb. Vasc. Biol. 19, 1257-1262 (1999).
59. Favari E, Gomaraschi M, Zanotti I et al. A unique protease-sensitive high density lipoprotein particle containing the apolipoprotein A-IMilano dimer effectively promotes ATP-binding cassette A1-mediated cell cholesterol efflux. J. Biol. Chem. 282, 5125-5132 (2007).
60. Nofer JR, Remaley AT. Tangier disease: still more questions than answers. Cell. Mol. Life Sci. 62, 2150-2160 (2005).
61. Kuivenhoven JA, Hovingh GK, van Tol A et al. Heterozygosity for ABCA1 gene mutations: effects on enzymes, apolipoproteins and lipoprotein particle size. Atherosclerosis 171, 311-319 (2003).
62. Altilia S, Pisciotta L, Garuti R et al. Abnormal splicing of ABCA1 pre-mRNA in Tangier disease due to a IVS2 +5G>C mutation in ABCA1 gene. J. Lipid Res. 44, 254-264 (2003).
63. van Dam MJ, de Groot E, Clee SM et al. Association between increased arterial-wall thickness and impairment in ABCA1-driven cholesterol efflux: an observational study. Lancet 359, 37-42 (2002).
64. Brunham LR, Singaraja RR, Hayden MR. Variations on a gene: rare and common variants in ABCA1 and their impact on HDL cholesterol levels and atherosclerosis. Annu. Rev. Nutr. 26, 105-129 (2006).
65. Brousseau ME, Bodzioch M, Schaefer EJ et al. Common variants in the gene encoding ATP-binding cassette transporter 1 in men with low HDL cholesterol levels and coronary heart disease. Atherosclerosis 154, 607-611 (2001).
66. Frikke-Schmidt R, Nordestgaard BG, Stene MC et al. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA 299, 2524-2532 (2008).
67. Calabresi L, Simonelli S, Gomaraschi M, Franceschini G. Genetic lecithin:cholesterol acyltransferase deficiency and cardiovascular disease. Atherosclerosis 222, 299-306 (2012).
68. Jonas A. Lecithin cholesterol acyltransferase. Biochim. Biophys. Acta 1529, 245-256 (2000).
69. Calabresi L, Pisciotta L, Costantin A et al. The molecular basis of lecithin:cholesterol acyltransferase deficiency syndromes: a comprehensive study of molecular and biochemical findings in 13 unrelated Italian families. Arterioscler. Thromb. Vasc. Biol. 25, 1972-1978 (2005).
70. Asztalos BF, Schaefer EJ, Horvath KV et al. Role of LCAT in HDL remodeling: investigation of LCAT deficiency states. J. Lipid Res. 48, 592-599 (2007).
71. Ayyobi AF, McGladdery SH, Chan S et al. Lecithin: cholesterol acyltransferase (LCAT) deficiency and risk of vascular disease: 25 year follow-up. Atherosclerosis 177, 361-366 (2004).
72. Hovingh GK, Hutten BA, Holleboom AG et al. Compromised LCAT function is associated with increased atherosclerosis. Circulation 112, 879-884 (2005).
73. Calabresi L, Baldassarre D, Castelnuovo S et al. Functional lecithin:cholesterol acyltransferase is not required for efficient atheroprotection in humans. Circulation 120, 628-635 (2009).
74. Dullaart RP, Perton F, van der Klauw MM, Hillege HL, Sluiter WJ. High plasma lecithin:cholesterol acyltransferase activity does not predict low incidence of cardiovascular events: possible attenuation of cardioprotection associated with high HDL cholesterol. Atherosclerosis 208, 537-542 (2010).
75. Calabresi L, Baldassarre D, Simonelli S et al. Plasma lecithin:cholesterol acyltransferase and carotid intima-media thickness in European individuals at high cardiovascular risk. J. Lipid Res. 52, 1569-1574 (2011).
76. Inazu A, Brown ML, Hesler CB et al. Increased high density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N. Engl. J. Med. 323, 1234-1238 (1990).
77. Calabresi L, Nilsson P, Pinotti E et al. A novel homozygous mutation in CETP gene as a cause of CETP deficiency in a Caucasian kindred. Atherosclerosis 205, 506-511 (2009).
78. Yamashita S, Maruyama T, Hirano K et al. Molecular mechanisms, lipoprotein abnormalities and atherogenicity of hyperalphalipoproteinemia. Atherosclerosis 152, 271-285 (2000).
79. Cefalu AB, Noto D, Magnolo L et al. Novel mutations of CETP gene in Italian subjects with hyeralphalipoproteinemia. Atherosclerosis 204, 202-207 (2009).
80. Barter PJ, Caulfield M, Eriksson M et al. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357, 2109-2122 (2007).
81. Schwartz GG, Olsson AG, Abt M et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N. Engl. J. Med. 367, 2089-2099 (2012).
82. de Grooth GJ, Klerkx AH, Stroes ES et al. A review of CETP and its relation to atherosclerosis. J. Lipid Res. 45, 1967-1974 (2004).
83. Ibanez B, Giannarelli C, Cimmino G et al. Recombinant HDL(Milano) exerts greater anti-inflammatory and plaque stabilizing properties than HDL(wild-type). Atherosclerosis 220, 72-77 (2012).
84. Galle J, Hansen-Hagge T, Wanner C, Seibold S. Impact of oxidized low density lipoprotein on vascular cells. Atherosclerosis 185, 219-226 (2006).
85. Daniil G, Phedonos AA, Holleboom AG et al. Characterization of antioxidant/anti-inflammatory properties and apoA I-containing subpopulations of HDL from family subjects with monogenic low HDL disorders. Clin. Chim. Acta 412, 1213-1220 (2011).
86. Bielicki JK, Oda MN. Apolipoprotein A-I(Milano) and apolipoprotein A-I(Paris) exhibit an antioxidant activity distinct from that of wild-type apolipoprotein A-I. Biochemistry 41, 2089-2096 (2002).
87. Holleboom AG, Daniil G, Fu X et al. Lipid oxidation in carriers of lecithin:cholesterol acyltransferase gene mutations. Arterioscler. Thromb. Vasc. Biol. 32, 3066-3075 (2012).
88. Chantepie S, Bochem AE, Chapman MJ, Hovingh GK, Kontush A. High-density lipoprotein (HDL) particle subpopulations in heterozygous cholesteryl ester transfer protein (CETP) deficiency: maintenance of antioxidative activity. PLoS ONE 7, e49336 (2012).
89. Johannsen TH, Kamstrup PR, Andersen RV et al. Hepatic lipase, genetically elevated high-density lipoprotein, and risk of ischemic cardiovascular disease. J. Clin. Endocrinol. Metab. 94, 1264-1273 (2009).
90. Voight BF, Peloso GM, Orho-Melander M et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 380, 572-580 (2012).